Novo Nordisk A/S (NVO), a major player in the healthcare sector, announced on Monday its plans to invest 8.5 billion Danish kroner to construct a new production facility in Odense, Denmark. Scheduled for completion in 2027, this initiative promises to generate 400 permanent jobs upon its finalization.
Currently, construction is underway, and at its peak, up to 1,000 external workers will be involved on-site.
The site will boast a cutting-edge production facility and warehouse designed to handle various product lines, particularly in the realm of rare diseases like haemophilia, both presently and looking forward.
Henrik Wulff, the executive vice president for Product Supply, Quality & IT at Novo Nordisk, commented, "This facility will employ advanced technology and innovative equipment to ensure the highest quality for patients and to satisfy the increasing global demand for our transformative medicines."
The material has been provided by InstaForex Company - www.instaforex.com
Currently, construction is underway, and at its peak, up to 1,000 external workers will be involved on-site.
The site will boast a cutting-edge production facility and warehouse designed to handle various product lines, particularly in the realm of rare diseases like haemophilia, both presently and looking forward.
Henrik Wulff, the executive vice president for Product Supply, Quality & IT at Novo Nordisk, commented, "This facility will employ advanced technology and innovative equipment to ensure the highest quality for patients and to satisfy the increasing global demand for our transformative medicines."
The material has been provided by InstaForex Company - www.instaforex.com